Latest Industry Insights

Technology Networks recently interviewed Anthony V. Lemmo, to learn how rapid antigen tests work, how they compare to PCR tests and how they can be used to help slow the spread of SARS-CoV-2.

Technology Networks had the pleasure of speaking with Ki-Sung Kwon, head of the R&D unit at Celltrion to learn more about therapeutic versus preventive strategies against COVID-19 and the company's monoclonal antibody-based therapeutic – CT-P59 – that is currently being developed against COVID-19.

Animal-free testing methods are being increasingly explored and implemented as an alternative to animal models, in efforts to provide a more accurate prediction of a drug candidate’s efficacy and safety. InSphero recently hosted a virtual roundtable discussion on the topic of animal-free testing. Technology Networks had the pleasure of speaking with Armin Wolf, chief scientific officer at InSphero, to learn more about the topics discussed.

Public health groups and leaders around the world are adopting different approaches for viral tracking and monitoring to halt the spread of novel SARS-CoV-2 variants.

The full impact that microplastics have on health and the environment is still not well understood, however, mounting evidence regarding their negative effects has made microplastics a topic of interest for scientists, governments and regulatory bodies. We spoke to Kathleen A. Young about microplastics detection techniques and technologies, the importance of standards and how regulations may come to fruition in the years to come.

Technology Networks recently had the pleasure of speaking to Seth Lederman, president and chief executive officer of Tonix Pharmaceuticals, to learn more about the T-cell response to SARS-CoV-2, how it compares to the antibody response and the importance of measuring it during the pandemic.

Technology Networks recently interviewed Benjamin Oakes, co-founder, president and CEO at Scribe, to learn more about the company's next steps in "fulfilling the promise of CRISPR" and how it will navigate some of the challenges associated with developing CRISPR-based therapeutics, including efficacy, scale-up and high costs.

A novel combination of miniaturized purification technology, automation and software presents an opportunity to drastically shorten drug or vaccine development timelines by rethinking how purification processes are refined.

To detect, quantify and ultimately instigate remedial action in relation to dioxin contamination, scientists require suitable analytical tools and techniques. The USEPA recently approved a new dioxin testing method which could assist these efforts. We spoke to Frank L. Dorman, PhD, FRSC, about the hazards posed by dioxins, challenges in their identification and the future detection landscape.

We interviewed Jan Davidson MD., PhD., the newly appointed chief medical officer at Wugen to learn more about the company's agreement with Washington University to further their Memory NK Cell program.